The Adapter Protein, Grb10, Is a Positive Regulator of Vascular Endothelial Growth Factor Signaling

Total Page:16

File Type:pdf, Size:1020Kb

The Adapter Protein, Grb10, Is a Positive Regulator of Vascular Endothelial Growth Factor Signaling Oncogene (2001) 20, 3959 ± 3968 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc The adapter protein, Grb10, is a positive regulator of vascular endothelial growth factor signaling S Giorgetti-Peraldi*,1, J Murdaca1, JC Mas1 and E Van Obberghen1 1INSERM U145, IFR 50, Faculte de MeÂdecine, avenue de Valombrose, 06107 Nice Cedex 2 France Vascular endothelial growth factor (VEGF) is an expressed only on endothelial cells, Flt-1 (Fms like important regulator of vasculogenesis and angiogenesis. tyrosine kinase) and Flk/KDR (Kinase insert domain Activation of VEGF receptors leads to the recruitment of containing receptor). Both receptors are structurally SH2 containing proteins which link the receptors to the related to the PDGF (Platelet Derived Growth Factor) activation of signaling pathways. Here we report that receptor family (Neufeld et al., 1999). Knock-out Grb10, an adapter protein of which the biological role studies have shown that these receptors have dierent remains unknown, is tyrosine phosphorylated in response biological functions. Indeed, in Flk null mice, to VEGF in endothelial cells (HUVEC) and in 293 cells endothelial and hematopoietic cell development is expressing the VEGF receptor KDR. An intact SH2 impaired. In Flt-1 knock-out mice, there is an apparent domain is required for Grb10 tyrosine phosphorylation in overgrowth of endothelial cells, and blood vessels are response to VEGF, and this phosphorylation is mediated disorganized (Fong et al., 1995; Shalaby et al., 1995). in part through the activation of Src. In HUVEC, VEGF These results and other studies performed by activating increases Grb10 mRNA level. Expression of Grb10 in separately only one receptor suggest that KDR is HUVEC or in KDR expressing 293 cells results in an involved in endothelial cell proliferation and survival, increase in the amount and in the tyrosine phosphoryla- while Flt-1 seems to be required for chemotaxis and tion of KDR. In 293 cells, this is correlated with the procoagulant activity. Although both receptors are activation of signaling molecules, such as MAP kinase. capable of autophosphorylation in vitro (Waltenberger By expressing mutants of Grb10, we found that the et al., 1994), only KDR autophosphorylates in vivo. positive action of Grb10 is independent of its SH2 The deletion of the tyrosine kinase domain of Flt-1 domain. Moreover, these Grb10 eects on KDR seem to does not impair blood vessel formation in homozygous be speci®c since Grb10 has no eect on the insulin mice, suggesting that the kinase domain of Flt-1 is not receptor, and Grb2, another adapter protein, does not required for its action on angiogenesis (Hiratsuka et mimic the eect of Grb10 on KDR. In conclusion, we al., 1998). propose that VEGF up-regulates Grb10 level, which in A series of steps in the VEGF signaling pathway turn increases KDR molecules, suggesting that Grb10 have been elucidated. Activation of VEGF receptors could be involved in a positive feedback loop in VEGF promotes tyrosine phosphorylation of several proteins, signaling. Oncogene (2001) 20, 3959 ± 3968. and recruitment of SH2-containing molecules (Walten- berger et al., 1994). Stimulation of KDR leads to PI-3- Keywords: Grb10; VEGF receptor; KDR; angiogenesis kinase and PKB activation (Gerber et al., 1998; Wu et al., 2000), to MAP kinase activation through PLCg and PKC-dependent pathway (Takahashi et al., 1999), Introduction to nitric oxide synthesis and to FAK tyrosine phosphorylation (Abedi and Zachary, 1997; Shen et Vascular Endothelial Growth Factor (VEGF) is al., 1999). However, many players in VEGF signaling involved in endothelial cell proliferation, microvascular have still to be discovered. Tyrosine kinase receptors permeability, vasodilatation and angiogenesis. Angio- control signaling pathways through association of SH2 genesis, the sprouting of new capillaries from existing containing proteins and tyrosine phosphorylated pro- vasculature, is necessary for vascular development, teins. wound healing, organ regeneration, and has been Grb10 protein contains several interaction motifs, involved in disease states such as diabetic retinopathy, such as a N-terminal proline-rich sequence, a central rheumatoid arthritis and tumor growth (Carmeliet, PH (Pleckstrin homology) domain, a BPS domain 2000; Ferrara and Davis, 1997; Risau, 1997). VEGF (Between PH and SH2) and a C-terminal SH2 domain binds to two speci®c tyrosine kinase receptors (Frantz et al., 1997; He et al., 1998; Ooi et al., 1995). Although Grb10 interacts with tyrosine kinase recep- tors such as PDGF, EGF, insulin and IGF-I receptors, its function as an adapter molecule remains to be *Correspondence: S Giorgetti-Peraldi Received 23 November 2000; revised 6 April 2001; accepted 9 April discovered (He et al., 1998; Stein et al., 1996). Indeed, 2001 Grb10 binds to signaling molecules such as Raf1, Involvement of Grb10 in VEGF signaling pathway S Giorgetti-Peraldi 3960 MEK1, BCR-Abl, Jak2, NEDD4 (Nantel et al., 1998; the conserved arginine 462 by a lysine. This mutant is Bai et al., 1998; Moutoussamy et al., 1998; Morrione et unable to associate with KDR in yeast two hybrid. All al., 1999), but the consequences of these associations the results show that Grb10 binds to KDR only have not been elucidated. The role of Grb10 in cellular through its SH2 domain. In each condition, the signaling is controversial. According to some authors, amount of expressed proteins was identical as revealed microinjection of the Grb10 SH2 domain decreases by Western blot (data not shown). We conclude that insulin- and IGF-I-mediated mitogenesis (Morrione et association of Grb10 to KDR is dependent on the al., 1997), while in other reports, Grb10 has a positive tyrosine kinase activity of the receptor, and requires a role in PDGF, IGF-I and insulin-induced mitogenesis functional SH2 domain of Grb10. (Wang et al., 1999). In this study, we show that Grb10 is tyrosine Grb10 is tyrosine phosphorylated in response to VEGF phosphorylated in response to VEGF in HUVEC and in 293 cells expressing KDR. Moreover, VEGF We studied whether Grb10 is tyrosine phosphorylated increases Grb10 mRNA in HUVEC. In 293 cells and in response to VEGF. Human endothelial cells in HUVEC, overexpression of Grb10 induces an (HUVEC) were stimulated with VEGF and tyrosine increase in the amount and in the tyrosine phosphor- phosphorylation of endogenous Grb10 was assessed ylation of KDR, coupled to an increase in the VEGF- after immunoprecipitation with an antibody to Grb10. induced MAP kinase activity. We show that Grb10 As shown in Figure 2a, VEGF treatment induces a interacts directly with VEGF receptor KDR, and that three-fold increase in Grb10 tyrosine phosphorylation. the SH2 domain of Grb10 mediates this association. To study the mechanism of this phosphorylation, we Since VEGF stimulates the expression of Grb10 expressed epitope-tagged Grb10-HA and KDR-Myc in mRNA, and Grb10 increases KDR molecules, we 293 cells (that lack endogenous VEGF receptors). Cells would like to suggest that a positive feed-back loop were stimulated with VEGF, and Grb10-HA was could exist. immunoprecipitated with an antibody to the HA epitope followed by an antiphosphotyrosine immuno- blot. As shown in Figure 2b, VEGF-induced activation of KDR stimulates Grb10 tyrosine phosphorylation. Results Grb10 phosphorylation is abolished when a SH2 domain de®cient mutant of Grb10 is expressed KDR interacts with Grb10 SH2 domain (Grb10 R462K) (Figure 2c). Although Grb10 binds to several tyrosine kinase Src is known to phosphorylate Grb10 on tyrosine receptors, its biological role remains unknown. To (Langlais et al., 2000). Moreover, Src kinases are elucidate the function of Grb10, we investigated its involved in VEGF signaling pathway (Eliceiri et al., implication in VEGF signaling. 1999). To study whether phosphorylation of Grb10 in VEGF binds to two tyrosine kinase receptors, Flt-1 response to VEGF could be due to Src, we treated and KDR. Since it has been shown that only KDR HUVEC with the Src inhibitor, PP2 prior to VEGF autophosphorylates in endothelial cells, we determined stimulation. We observed that PP2 treatment of whether KDR interacts with Grb10 using the yeast two HUVEC did not aect the VEGF-induced tyrosine hybrid system. KDR cDNA corresponding to the phosphorylation of KDR (Figure 3a). Grb10 was cytoplasmic domain of the receptor was subcloned in immunoprecipitated and analysed by antiphosphotyr- frame with the binding domain of LexA. Grb10 cDNA osine immunoblot (Figure 3b). PP2 treatment of was subcloned in frame with the activation domain of HUVEC induces a 40% decrease in the VEGF induced Gal-4. Yeasts were co-transformed by the two hybrids, tyrosine phosphorylation of Grb10. However, the and the association between the proteins was measured tyrosine phosphorylation of Grb10 is not totally by the transactivation of a reporter gene, LacZ. Results blocked suggesting that both Src and KDR are in Figure 1a, show that pLex-KDR interacts with involved in the tyrosine phosphorylation of Grb10 pAct-Grb10 as compared to a negative control, Raf. after VEGF stimulation. In conclusion, Grb10 is This interaction is dependent on the tyrosine kinase tyrosine phosphorylated in response to VEGF. This activity of the receptor, since the generation of a phosphorylation seems to be due to both an action of kinase-dead mutant (KD) of KDR by replacement of KDR and Src. lysine 868 by alanine, abolishes the interaction of KDR with Grb10 in the yeast two hybrid system. Grb10 mRNA is increased by VEGF To localize the binding site on Grb10, we generated several mutants of pACT-Grb10 (Figure 1b). As Since Grb10 seems to be involved in VEGF signaling, represented, Grb10 possesses a proline-rich region, a we investigated whether VEGF could modulate Grb10 PH domain, a BPS region and a SH2 domain. All the expression. Endothelial cells (HUVEC) were treated deletion mutants of Grb10 were tested for their abilities with VEGF for 2, 4 and 6 h, RNA were extracted, and to bind to pLex-KDR (Figure 1c).
Recommended publications
  • SRC Antibody - N-Terminal Region (ARP32476 P050) Data Sheet
    SRC antibody - N-terminal region (ARP32476_P050) Data Sheet Product Number ARP32476_P050 Product Name SRC antibody - N-terminal region (ARP32476_P050) Size 50ug Gene Symbol SRC Alias Symbols ASV; SRC1; c-SRC; p60-Src Nucleotide Accession# NM_005417 Protein Size (# AA) 536 amino acids Molecular Weight 60kDa Product Format Lyophilized powder NCBI Gene Id 6714 Host Rabbit Clonality Polyclonal Official Gene Full Name V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) Gene Family SH2D This is a rabbit polyclonal antibody against SRC. It was validated on Western Blot by Aviva Systems Biology. At Aviva Systems Biology we manufacture rabbit polyclonal antibodies on a large scale (200-1000 Description products/month) of high throughput manner. Our antibodies are peptide based and protein family oriented. We usually provide antibodies covering each member of a whole protein family of your interest. We also use our best efforts to provide you antibodies recognize various epitopes of a target protein. For availability of antibody needed for your experiment, please inquire (). Peptide Sequence Synthetic peptide located within the following region: QTPSKPASADGHRGPSAAFAPAAAEPKLFGGFNSSDTVTSPQRAGPLAGG This gene is highly similar to the v-src gene of Rous sarcoma virus. This proto-oncogene may play a role in the Description of Target regulation of embryonic development and cell growth. SRC protein is a tyrosine-protein kinase whose activity can be inhibited by phosphorylation by c-SRC kinase. Mutations in this gene could be involved in the
    [Show full text]
  • Mitochondrial Membrane Binding and Protein Complexing of the Anti-Apoptotic Adaptor Protein Grblo
    Mitochondrial membrane binding and protein complexing of the anti-apoptotic adaptor protein GrblO. by Jennifer Hassard Department of Biology McGill University, Montreal A thesis submitted to the Faculty of Graduate Studies and Research in partial fulfillment of the requirements for the degree of Master's of Science August 2001 Supervisor: Dr. David Thomas, Department of Biochemistry © Jennifer Hassard, 2001 .....--. National Library Bibliothèque nationale 1+1 of Canada du Canada Acquisitions and Acquisitions et Bibliographie Services services bibliographiques 395 Wellington Street 395. rue Wellington OttawaON K1A0N4 Ottawa ON K1 A ON4 canada canada Your liIe VoIJ8 rrlfénJnce Our liIe Notre rtifénlncs The author has granted a non­ L'auteur a accordé une licence non exclusive licence al10wing the exclusive permettant à la National Library ofCanada to Bibliothèque nationale du Canada de reproduce, loan, distribute or sell reproduire, prêter, distribuer ou copies ofthis thesis in microform, vendre des copies de cette thèse sous paper or electronic formats. la forme de microfiche/film, de reproduction sur papier ou sur format électronique. The author retains ownership ofthe L'auteur conserve la propriété du copyright in this thesis. Neither the droit d'auteur qui protège cette thèse. thesis nor substantial extracts from it Ni la thèse ni des extraits substantiels may be printed or otherwise de celle-ci ne doivent être imprimés reproduced without the autbor's ou autrement reproduits sans son penmsslon. autorisation. 0-612-78889-X Canada ABSTRACT GrblO is a member of the Grb7 family of adaptor proteins that also includes Grb7 and Grb14. These three members contain multiple protein binding domains and lack enzymatic activity.
    [Show full text]
  • Stimulation of Endogenous GH and Interleukin-6 Receptors Selectively Activates Different Jaks and Stats, with a Stat5 Specific Synergistic Effect of Dexamethasone
    301 Stimulation of endogenous GH and interleukin-6 receptors selectively activates different Jaks and Stats, with a Stat5 specific synergistic effect of dexamethasone S von Laue1, J Finidori3, M Maamra1, X-Y Shen1, S Justice1, P R M Dobson2 and R J M Ross1 1Division of Clinical Sciences, University of Sheffield, UK 2Institute for Cancer Studies, University of Sheffield, UK 3INSERM, Unité 344, Faculté de Médecine Necker, Paris, France (Requests for offprints should be addressed to S von Laue, INSERM U344, Laboratoire d’Endocrinologie Moléculaire, Faculté de Médecine Necker-Enfants Malades, 156, rue de Vaugirard, 75 730 Paris cedex 15, France; Email: [email protected]) Abstract The interaction of GH, interleukin (IL)-6 and glucocorti- Stat3 activation. In contrast, the reporter gene containing coids is likely to be important in regulating the GH- the Stat3 responsive element (SIE) was IL-6 specific. The insulin-like growth factor (IGF)-I axis. The signalling levels of gene induction by GH and IL-6 were not altered cascades activated by GH and IL-6 appear to be very by the co-stimulation with GH and IL-6, suggesting that similar, as demonstrated by studies using overexpression of there is little cross-talk at the Jak–Stat activation level the receptor and other components of the Jak-Stat and between the two cytokines. Neither GH nor IL-6 acti- mitogen-activated protein (MAP) kinase pathways. Here vated the MAP-kinase responsive serum response element we show that the human embryonic kidney cell line 293 (SRE), unless GH receptors or gp130 were overexpressed. (HEK293) expresses GH and IL-6 receptors endogenously.
    [Show full text]
  • Increased in Vivo Phosphorylation of Ret Tyrosine 1062 Is a Potential Pathogenetic Mechanism of Multiple Endocrine Neoplasia Type 2B1
    [CANCER RESEARCH 61, 1426–1431, February 15, 2001] Increased in Vivo Phosphorylation of Ret Tyrosine 1062 Is a Potential Pathogenetic Mechanism of Multiple Endocrine Neoplasia Type 2B1 Domenico Salvatore, Rosa Marina Melillo, Carmen Monaco, Roberta Visconti, Gianfranco Fenzi, Giancarlo Vecchio, Alfredo Fusco, and Massimo Santoro2 Centro di Endocrinologia ed Oncologia Sperimentale del CNR, c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare [D. S., R. M. M., C. M., R. V., G. V., M. S.], and Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Facolta` di Medicina e Chirurgia [G. F.], Universita` di Napoli “Federico II,” Naples, Italy; and Dipartimento di Medicina Sperimentale e Clinica, Facolta`di Medicina e Chirurgia di Catanzaro, Universita`di Catanzaro, Catanzaro [A. F], Italy ABSTRACT are responsible for the inheritance of MEN2A and MEN2B and FMTC. Each disease has a distinct phenotype: MEN2A is associated Mutations of the Ret receptor tyrosine kinase are responsible for with MTC, pheochromocytoma, and parathyroid hyperplasia. The inheritance of multiple endocrine neoplasia (MEN2A and MEN2B) and MEN2B phenotype is more severe, being characterized by an earlier familial medullary thyroid carcinoma syndromes. Although several famil- ial medullary thyroid carcinoma and most MEN2A mutations involve occurrence of more aggressive MTC. Unlike MEN2A patients, substitutions of extracellular cysteine residues, in most MEN2B cases MEN2B patients develop multiple mucosal neuromas and several there is a methionine-to-threonine substitution at position 918 (M918T) of skeletal abnormalities. Finally, FMTC consists only of an inherited the Ret kinase domain. The mechanism by which the MEN2B mutation predisposition to MTC (3). Involvement of different tissues corre- converts Ret into a potent oncogene is poorly understood.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • ITRAQ-Based Quantitative Proteomic Analysis of Processed Euphorbia Lathyris L
    Zhang et al. Proteome Science (2018) 16:8 https://doi.org/10.1186/s12953-018-0136-6 RESEARCH Open Access ITRAQ-based quantitative proteomic analysis of processed Euphorbia lathyris L. for reducing the intestinal toxicity Yu Zhang1, Yingzi Wang1*, Shaojing Li2*, Xiuting Zhang1, Wenhua Li1, Shengxiu Luo1, Zhenyang Sun1 and Ruijie Nie1 Abstract Background: Euphorbia lathyris L., a Traditional Chinese medicine (TCM), is commonly used for the treatment of hydropsy, ascites, constipation, amenorrhea, and scabies. Semen Euphorbiae Pulveratum, which is another type of Euphorbia lathyris that is commonly used in TCM practice and is obtained by removing the oil from the seed that is called paozhi, has been known to ease diarrhea. Whereas, the mechanisms of reducing intestinal toxicity have not been clearly investigated yet. Methods: In this study, the isobaric tags for relative and absolute quantitation (iTRAQ) in combination with the liquid chromatography-tandem mass spectrometry (LC-MS/MS) proteomic method was applied to investigate the effects of Euphorbia lathyris L. on the protein expression involved in intestinal metabolism, in order to illustrate the potential attenuated mechanism of Euphorbia lathyris L. processing. Differentially expressed proteins (DEPs) in the intestine after treated with Semen Euphorbiae (SE), Semen Euphorbiae Pulveratum (SEP) and Euphorbiae Factor 1 (EFL1) were identified. The bioinformatics analysis including GO analysis, pathway analysis, and network analysis were done to analyze the key metabolic pathways underlying the attenuation mechanism through protein network in diarrhea. Western blot were performed to validate selected protein and the related pathways. Results: A number of differentially expressed proteins that may be associated with intestinal inflammation were identified.
    [Show full text]
  • Metabolic Imaging Allows Early Prediction of Response to Vandetanib
    Metabolic Imaging Allows Early Prediction of Response to Vandetanib Martin A. Walter1,2,MatthiasR.Benz2,IsabelJ.Hildebrandt2, Rachel E. Laing2, Verena Hartung3, Robert D. Damoiseaux4, Andreas Bockisch3, Michael E. Phelps2,JohannesCzernin2, and Wolfgang A. Weber2,5 1Institute of Nuclear Medicine, University Hospital, Bern, Switzerland; 2Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; 3Institute of Nuclear Medicine, University Hospital, Essen, Germany; 4Molecular Shared Screening Resources, UCLA, Los Angeles, California; and 5Department of Nuclear Medicine, University Hospital, Freiburg, Germany The RET (rearranged-during-transfection protein) protoonco- The RET (rearranged-during-transfection protein) proto- gene triggers multiple intracellular signaling cascades regulat- oncogene, located on chromosome 10q11.2, encodes for ing cell cycle progression and cellular metabolism. We therefore a tyrosine kinase of the cadherin superfamily that activates hypothesized that metabolic imaging could allow noninvasive detection of response to the RET inhibitor vandetanib in vivo. multiple intracellular signaling cascades regulating cell sur- Methods: The effects of vandetanib treatment on the full- vival, differentiation, proliferation, migration, and chemo- genome expression and the metabolic profile were analyzed taxis (1). Gain-of-function mutations in the RET gene result in the human medullary thyroid cancer cell line TT. In vitro, tran- in uncontrolled growth and cause human cancers and scriptional changes of pathways regulating cell cycle progres- cancer syndromes, such as Hu¨rthle cell cancer, sporadic sion and glucose, dopa, and thymidine metabolism were papillary thyroid carcinoma, familial medullary thyroid correlated to the results of cell cycle analysis and the uptake of 3H-deoxyglucose, 3H-3,4-dihydroxy-L-phenylalanine, and carcinoma, and multiple endocrine neoplasia types 2A 3H-thymidine under vandetanib treatment.
    [Show full text]
  • SUPPLEMENTARY METHODS Cell Culture.-Human Peripheral Blood
    SUPPLEMENTARY METHODS Cell culture.-Human peripheral blood mononuclear cells (PBMC) were isolated from buffy coats from normal donors over a Lymphoprep (Nycomed Pharma) gradient. Monocytes were purified from PBMC by magnetic cell sorting using CD14 microbeads (Miltenyi Biotech). Monocytes were cultured at 0.5 x 106 cells/ml for 7 days in RPMI 1640 (standard RPMI, which contains 1 mg/L folic acid) supplemented with 10% fetal calf serum, at 37ºC in a humidified atmosphere with 5% CO2, and containing GM-CSF (1000U/ml) or M-CSF (10 ng/ml, ImmunoTools) to generate GM-CSF- polarized macrophages (GM-MØ) or M-CSF-polarized macrophages (M-MØ). MTX pharmacokinetic studies in RA patients administered 25 mg MTX showed peak plasma levels of 1-2 µM MTX two hours after drug administration, but plasma levels decline to 10-50 nM MTX within 24-48 hours [1, 2]. MTX (50 nM), pemetrexed (PMX, 50 nM), folic acid (FA, 50 nM) [3], thymidine (dT, 10 µM), pifithrin-α (PFT, 25-50 µM), nutlin-3 (10 µM, Sigma-Aldrich) was added once on monocytes together with the indicated cytokine, or on monocytes and 7-day differentiated macrophages for 48h. Gene expression profiling.-For long-term MTX treatment, RNA was isolated from three independent preparations of monocytes either unexposed or exposed to MTX (50 nM) and differentiated to GM-MØ or M-MØ for 7-days. For short-term schedule, RNA was isolated from three independent samples of fully differentiated GM-MØ either unexposed or exposed to MTX (50 nM) for 48h, by using RNeasy Mini kit (QIAGEN).
    [Show full text]
  • Characterization of the Full-Length Human Grb7 Protein, and A
    Characterization of the full-length human Grb7 protein and a phosphorylation representative mutant Item Type Article Authors Bradford, Andrew M; Koirala, Rajan; Park, Chad K; Lyons, Barbara A Citation Bradford, AM, Koirala, R, Park, CK, Lyons, BA. Characterization of the fulllength human Grb7 protein and a phosphorylation representative mutant. J Mol Recognit. 2019;e2803. https:// doi.org/10.1002/jmr.2803 DOI 10.1002/jmr.2803 Publisher WILEY Journal JOURNAL OF MOLECULAR RECOGNITION Rights © 2019 John Wiley & Sons, Ltd. Download date 27/09/2021 08:45:31 Item License http://rightsstatements.org/vocab/InC/1.0/ Version Final accepted manuscript Link to Item http://hdl.handle.net/10150/634134 Characterization of the full-length human Grb7 protein, and a phosphorylation representative mutant Andrew M. Bradforda, Rajan Koiralac, Chad K. Parkb, and Barbara A. Lyonsc* aAgena Bioscience, 4755 Eastgate Mall, San Diego, CA 92121; bAnalytical Biophysics Core, Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ 85721; cDepartment of Chemistry and Biochemistry, New Mexico State University, Las Cruces, NM 88003 Correspondence should be addressed to: Dr. Barbara A. Lyons Department of Chemistry and Biochemistry MSC 3C, P.O. Box 30001 Las Cruces, New Mexico 88003-8001 575-636-4072 [email protected] Abstract It is well known the dimerization state of receptor tyrosine kinases (RTKs), in conjunction with binding partners such as the Grb7 protein, plays an important role in cell signaling regulation. Previously we proposed, downstream of RTKs, that the phosphorylation state of Grb7SH2 domain tyrosine residues could control Grb7 dimerization, and dimerization may be an important regulatory step in Grb7 binding to RTKs.
    [Show full text]
  • Spatial and Temporal Aspects and the Interplay of Grb14 and Protein
    Rajala et al. Cell Communication and Signaling 2013, 11:96 http://www.biosignaling.com/content/11/1/96 RESEARCH Open Access Spatial and temporal aspects and the interplay of Grb14 and protein tyrosine phosphatase-1B on the insulin receptor phosphorylation Raju VS Rajala1,2,3,4*, Devaraj K Basavarajappa1,4,5, Radhika Dighe1,4 and Ammaji Rajala1,4 Abstract Background: Growth factor receptor-bound protein 14 (Grb14) is an adapter protein implicated in receptor tyrosine kinase signaling. Grb14 knockout studies highlight both the positive and negative roles of Grb14 in receptor tyrosine kinase signaling, in a tissue specific manner. Retinal cells are post-mitotic tissue, and insulin receptor (IR) activation is essential for retinal neuron survival. Retinal cells express protein tyrosine phosphatase-1B (PTP1B), which dephosphorylates IR and Grb14, a pseudosubstrate inhibitor of IR. This project asks the following major question: in retinal neurons, how does the IR overcome inactivation by PTP1B and Grb14? Results: Our previous studies suggest that ablation of Grb14 results in decreased IR activation, due to increased PTP1B activity. Our research propounds that phosphorylation in the BPS region of Grb14 inhibits PTP1B activity, thereby promoting IR activation. We propose a model in which phosphorylation of the BPS region of Grb14 is the key element in promoting IR activation, and failure to undergo phosphorylation on Grb14 leads to both PTP1B and Grb14 exerting their negative roles in IR. Consistent with this hypothesis, we found decreased phosphorylation of Grb14 in diabetic type 1 Ins2Akita mouse retinas. Decreased retinal IR activation has previously been reported in this mouse line.
    [Show full text]
  • Tissue-Specific Regulation and Function of Grb10 During Growth And
    PAPER Tissue-specific regulation and function of Grb10 during COLLOQUIUM growth and neuronal commitment Robert N. Plasschaert and Marisa S. Bartolomei1 Department of Cell & Developmental Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104 Edited by Eric B. Keverne, University of Cambridge, Cambridge, United Kingdom, and accepted by the Editorial Board September 23, 2014 (received for review July 29, 2014) Growth-factor receptor bound protein 10 (Grb10) is a signal factor, which is recruited in a DNA methylation-sensitive manner adapter protein encoded by an imprinted gene that has roles in and has been implicated in the regulation of imprinted expression growth control, cellular proliferation, and insulin signaling. Addi- at other loci (Fig. 1A). tionally, Grb10 is critical for the normal behavior of the adult Thus, Grb10 is an imprinted gene with multiple functions and mouse. These functions are paralleled by Grb10’s unique tissue- a complex tissue-specific imprinted expression pattern. Here, we specific imprinted expression; the paternal copy of Grb10 is review work that has illuminated the functional roles of Grb10 in expressed in a subset of neurons whereas the maternal copy is embryonic development, cellular growth, and behavior. We also expressed in most other adult tissues in the mouse. The mecha- review the various regulatory mechanisms that have been implicated nism that underlies this switch between maternal and paternal in the control of Grb10 tissue-specific expression and imprinting. expression is still unclear, as is the role for paternally expressed Additionally, we present data addressing the regulation of Grb10 Grb10 in neurons. Here, we review recent work and present com- expression during neuronal development in vitro.
    [Show full text]
  • Grb7, a Critical Mediator of EGFR/Erbb Signaling, in Cancer Development and As a Potential Therapeutic Target
    cells Review Grb7, a Critical Mediator of EGFR/ErbB Signaling, in Cancer Development and as a Potential Therapeutic Target 1, 1,2, 1,3, Pei-Yu Chu y , Yu-Ling Tai y and Tang-Long Shen * 1 Department of Plant Pathology and Microbiology, National Taiwan University, Taipei 10617, Taiwan; [email protected] (P.-Y.C.); [email protected] (Y.-L.T.) 2 Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA 3 Center for Biotechnology, National Taiwan University, Taipei 10617, Taiwan * Correspondence: [email protected]; Tel.: +886-2-3366-4998 These authors contributed equally to this work. y Received: 30 March 2019; Accepted: 9 May 2019; Published: 10 May 2019 Abstract: The partner of activated epidermal growth factor receptor (EGFR), growth factor receptor bound protein-7 (Grb7), a functionally multidomain adaptor protein, has been demonstrated to be a pivotal regulator for varied physiological and pathological processes by interacting with phospho-tyrosine-related signaling molecules to affect the transmission through a number of signaling pathways. In particular, critical roles of Grb7 in erythroblastic leukemia viral oncogene homolog (ERBB) family-mediated cancer development and malignancy have been intensively evaluated. The overexpression of Grb7 or the coamplification/cooverexpression of Grb7 and members of the ERBB family play essential roles in advanced human cancers and are associated with decreased survival and recurrence of cancers, emphasizing Grb70s value as a prognostic marker and a therapeutic target. Peptide inhibitors of Grb7 are being tested in preclinical trials for their possible therapeutic effects. Here, we review the molecular, functional, and clinical aspects of Grb7 in ERBB family-mediated cancer development and malignancy with the aim to reveal alternative and effective therapeutic strategies.
    [Show full text]